GeoVax Labs, Inc. Annual Performance Review

I’ve put together this guide to help you understand GeoVax Labs’ performance over the past year. My goal is to translate technical filings into a simple conversation so you can decide if this company fits your investment goals.

1. What does this company do and how did they perform?

GeoVax Labs is a biotechnology company in the clinical testing phase. They use their proprietary platform to develop vaccines and immunotherapies. Because they have no products for sale, they generate almost no revenue—reporting only about $0.1 million in grant money this year. Their performance is measured by their progress in clinical trials and their ability to maintain the cash reserves necessary to fund operations until they reach a commercial milestone or secure a partner.

2. Financial performance

GeoVax is currently prioritizing research over profit. In 2025, they spent $18.1 million on research and development. While this is lower than the $23.7 million spent in 2024, the decrease reflects the completion of specific trial phases. Their loss for the year was approximately $22.5 million. As their lead projects move into larger, more expensive trials, these costs are expected to rise.

3. Major wins and challenges

• GEO-MVA (Mpox/Smallpox Vaccine): This is their primary asset. European regulators created a path for GeoVax to skip certain early-stage trials, accelerating their entry into a final Phase 3 study and potentially cutting their time-to-market by up to two years.
• Gedeptin® (Cancer Therapy): This gene therapy received "Fast Track" status from the FDA. The company is preparing for a Phase 2 trial in 2027, which will require $8–$10 million in new funding.
• COVID-19 Vaccine (GEO-CM04S1): Data showed their vaccine created a stronger immune response in high-risk patients than standard boosters. However, the government terminated a contract worth up to $24.9 million in April 2025, removing a key source of non-dilutive funding and increasing the company's reliance on selling new shares.

4. Financial health

GeoVax maintains a fragile balance sheet. As of late 2025, they held about $12.4 million in cash. To maintain compliance with Nasdaq listing requirements, they executed a 1-for-20 reverse stock split in early 2026. They currently use an "at-the-market" facility to sell shares periodically, which provides necessary capital but increases the total share count and reduces individual ownership percentages.

5. Key risks

• Funding: With a burn rate of roughly $1.5 million per month, the company has less than a year of cash remaining without securing additional financing.
• Manufacturing: They rely on third-party manufacturers; any disruption at these external sites could halt their clinical progress.
• Patents: Core technology patents begin expiring in the mid-2030s. Their long-term competitive advantage depends on securing new intellectual property.
• Operational Scale: With a team of only 19 employees, the company is highly dependent on the retention of key scientific personnel.

6. Competitive positioning

GeoVax competes against much larger pharmaceutical firms. They utilize "Orphan Drug" status for their cancer therapies to gain seven years of market exclusivity upon approval. Their business model relies on licensing technology from the City of Hope and the NIH, which necessitates ongoing royalty payments.

7. Leadership and strategy

The company employs a "lean-expert" model. They have expanded their Scientific Advisory Board with specialists from top universities to provide high-level oversight while keeping internal staffing costs low.

8. Future outlook

The company’s roadmap is strictly clinical. They currently have no sales force or marketing budget. Their 2026–2027 outlook depends on initiating the Phase 3 trial for GEO-MVA and securing the capital required for the Gedeptin trial. Success is binary: they must either reach a deal with a major pharmaceutical partner or continue to issue new shares to sustain operations.

9. Market trends

The company is highly sensitive to FDA and EMA regulatory decisions. While industry trends favoring faster approval for infectious disease vaccines are beneficial, any new safety requirements could force the company to restart expensive studies, which would rapidly deplete their remaining cash.

Investor Takeaway: GeoVax is a high-risk, high-reward "binary" play. Because they are not yet generating revenue, your investment is essentially a bet on their ability to successfully navigate clinical trials and either find a deep-pocketed partner or raise enough capital to reach the market without diluting shareholders too heavily. Keep a close eye on their cash burn and any announcements regarding Phase 3 trial progress.